Phosphorylation of the Twist1-Family Basic Helix-Loop-Helix Transcription Factors Is Involved in Pathological Cardiac Remodeling

Shuangshuang Lu1*, Junwei Nie1, Qing Luan1, Qiuting Feng1, Qi Xiao1, Zai Chang1, Congjia Shan1, Daniel Hess2, Brian A. Hemmings2, Zhongzhou Yang1

1 The Ministry of Education Key Laboratory of Model Animal for Disease Study, Model Animal Research Center, Nanjing University, Nanjing, China, 2 The Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland

Abstract

Background: The Twist1-family basic helix-loop-helix (bHLH) transcription factors including Twist1, Hand1 and Hand2, play an essential role in heart development and are implicated in pathological heart remodeling. Previously, it was reported that these bHLH transcription factors can be regulated by phosphorylation within the basic-helix I domain, which is involved in developmental processes such as limb formation and trophoblast differentiation. However, how phosphorylation of Twist1 family functions in post-natal heart is elusive.

Principal Findings: Here, we generated transgenic mice with over-expression of Hand1 and Twist1 mutants (to mimic or to abolish phosphorylation) in cardiomyocytes and found pathological cardiac remodeling leading to heart failure and sudden death. Gene expression profile analysis revealed up-regulation of growth-promoting genes and down-regulation of metabolic genes. It is well known that aberrant activation of Akt signaling causes pathological cardiac remodeling and results in heart failure. The basic-helix I domain of Twist1 family members contain Akt substrate consensus motif and may be downstream targets of Akt signaling. Using biochemical analysis, we demonstrated that Hand1 and Twist1 were phosphorylated by Akt in the basic-helix I domain. Phosphorylation of Hand1 regulated its transcriptional activation of luciferase reporter genes and DNA binding ability.

Conclusions: This study provides novel insights into the regulation of Twist1 family in cardiac remodeling and suggests that the Twist1 family can be regulated by Akt signaling.

Introduction

The Twist family of basic helix-loop-helix (bHLH) transcription factors including Twist1/2, Hand1/2, Scleraxis and Paraxis, play a variety of roles in both embryonic development and diseases [1,2,3,4]. Among the Twist1 family members, Twist1 and Hand1 (also termed eHand, Hxt and Thing1) have been intensively studied [2,5,6,7,8]. Biochemical studies have demonstrated that Twist1 and Hand1/2 formed hetero-dimers or homo-dimer with E12, E47 and between themselves to activate or suppress transcription of downstream target genes through binding E-box sequences such as the degenerate Thing1-box, CGTCTG, in the cis-regulatory elements of target genes [1,6,9,10,11].

Protein phosphorylation plays an important role in regulating the activity and function of Twist1 family members. Firulli and colleagues first reported that PKA, PKC and PP2A (containing the B56 regulatory subunit) could regulate phosphorylation of Hand1 and Hand2, which controlled trophoblast cell line RCHO1 differentiation [12]. In a following study, Firulli’s group demonstrated that phosphorylation regulates Twist1-Hand1 dimerization and the results suggested that the partner choice of Twist1 family protein dimerization is controlled by post-translational modification, which is crucial for normal development [9]. Hand1 was also reported to be phosphorylated by polo-like kinase Plk4 (Sak), which regulated Hand1 cellular localization and determined cell fate [13]. A recent study showed that phosphorylation of Twist1 affected its dimer affinity for a given partner and modulated the DNA binding affinity, which might control limb development [10].

Both Hand1 and Hand2 are essential for heart development as either germ-line or cardiac-specific deletion of Hand1 and Hand2 in mice causes heart defects and mortality [5,8,14,15]. Hand1 was also found to play a role in pathological heart remodeling in human and rodent models [16,17]. Although phosphorylation of...
Twist1 family is important for embryonic development, its role in post-natal heart function and remodeling remains elusive. For this purpose, we generated transgenic mice with over-expression of Hand1 and Twist1 wild-type and mutants (to mimic and to abolish phosphorylation) in cardiomyocytes and found pathological heart remodeling.

Akt signaling plays an important role in heart function, which has been intensively investigated in the past decade [18,19,20,21,22,23]. Aberrant activation of Akt signaling gives rise to pathological cardiac remodeling including hypertrophy and heart enlargement that leads to heart failure [24,25,26,27,28,29]. However, the downstream targets of Akt signaling involved in heart remodeling are not well known [30]. The basic helix I domain of Twist1 family proteins contain a well-conserved Akt substrate consensus motif suggesting that they are putative Akt substrates. Through biochemical and cell transfection assays, we demonstrated that both Twist1 and Hand1 could be phosphorylated by Akt, and phosphorylation regulated their transcriptional activity and DNA binding affinity. This study provides novel insights into the regulation of Twist1 family in cardiac remodeling and suggests that the Twist1 family can be regulated by Akt signaling.

**Results**

**Mice over-expressing Hand1 and Twist1 mutants in cardiomyocytes developed pathological cardiac remodeling**

The Twist1 family members of Hand1, Hand2, Twist1 and Twist2 possess a well-conserved basic-helix I motif that contains threonin and serine (Figure 1A). Therefore, phosphorylation of Twist1 family may play a role in post-natal heart function. To investigate this, we first generated transgenic (TG) mice expressing Hand1-WT, -AA and -DD specifically in cardiomyocytes (Figure 1B). Several lines of TG mice were obtained with distinct expression levels of all three Hand1 genes (Figure 1C and Figure S1C). Two mice lines expressing high-level Hand1-DD (designated DD63hyp and DD68hyp) displayed heart hypertrophy at 1 month that became more severe at 2 months (Figure 1D–F). The majority of these mice died at 2–3 months and showed heart hypertrophy and dilation (Figure 1D–F). Two lines with a relatively low Hand1-DD expression (designated DD68hyp and DD68hyp) developed heart hypertrophy at 2 months and the majority of these mice died at 4–5 months (Figure 1E and 1F). Echocardiography (Echo) tests on Hand1-DD mice indicated a reduction in heart contractility and function at 8–10 weeks (Table 1). These results showed a dose-dependent effect of Hand1-DD. Two TG lines of Hand1-AA (including Hand1-AA1high and –AA2high) displayed similar phenotypes: their hearts were relatively small at 2 months, showing slight dilation and a reduction in heart function (Figure 1D–F and Table 1). At 4–5 months, the Hand1-AA TG mice developed heart dilation and enlargement. Hand1-AA and –DD TG mice showed increased cardiomyocyte size and fibrosis (Figure 1H). Both Hand1-AA and -DD hearts displayed cardiomyocyte hypertrophy and fibrosis in the left ventricular free wall at 2 months (Figure 1H and I). These results indicate that aberrant phosphorylation (lower or higher) of Hand1 caused pathological heart remodeling.

We collected hearts from these Hand1 TG mice and performed microarray analysis to study gene expression profile. We found up-regulation of several key growth-promoting genes such as Fgfr1, Fgf12, Igf1r, Igf1, and Cyclin D2 (Cond2) in Hand1-DD hearts compared to Hand1-TG hearts (Table S1). RT-PCR result confirmed increased Cyclin D1 and D2 in Hand1-DD hearts (Figure S1A and S1B). Interestingly, genes involved in oxidative phosphorylation and citrate cycle (TCA cycle) were found with reduced expression in Hand1-DD hearts (Table S1). Cyclin D1 (Cond1) and cyclin D2 (Cond2) were also up-regulated in Hand1-DD hearts and genes encoding collagen isoforms were high in both Hand1-DD and –AA hearts consistent with fibrosis revealed by histological study (Table S1 and Figure 1H).

We first detected Twist1 expression in mouse tissues by RT-PCR and the result indicated that Twist1 was ubiquitously expressed with varied amount (Figure 2A). In particular, we found that Twist1 was expressed in heart ventricles (Figure 2A). Using a similar strategy for generation of Hand1 TG mice, we obtained Twist1-WT and -DD transgenic TG mice and found that while WT TG mice had comparable heart to control mice, Twist1-DD TG mice displayed hyper trophy and some of them had atrial septal defect (ASD) and ventricular septal defect (VSD) (Figure 2B–D). Echo analysis indicated impaired heart function in Twist1-DD mice compared to WT mice (Table 2 and Figure 2E and 2F).

**Hand1 and Twist1 could be phosphorylated by Akt in vitro and in vivo**

In the past decade, the role of Akt signaling in post-natal heart remodeling has been intensively investigated using Akt transgenic mouse models [24,25,26,27,28,29]. These studies have demonstrated that hyper-activation of Akt in cardiomyocytes caused severe pathological cardiac remodeling leading to heart failure [32]. Bioinformatic study using a computer program called Scansite (http://scansite.mit.edu) has predicted a well-conserved Akt substrate consensus motif in the basic-helix I domain of the Twist1 family members (Figure 1A) [33]. Gene expression analysis indicated increased expression levels of Igf1 and its receptor Igf1r that activated Akt signaling pathway (Table 2). Therefore, the Twist1 family could be regulated by Akt and might be involved in heart remodeling.

An in vitro phosphorylation assay using GST-Hand1 fusion protein demonstrated that mouse Hand1 could be phosphorylated by Akt at two residues, T107 and S109 (Figure 3A). Mutation of Thr107 and Ser109 of Hand1 caused pathological heart remodeling.

We collected hearts from these Hand1 TG mice and performed microarray analysis to study gene expression profile. We found up-regulation of several key growth-promoting genes such as Fgfr1, Fgf12, Igf1r, Igf1 and Cyclin D2 (Cond2) in Hand1-DD hearts compared to Hand1-TG hearts (Table S1). RT-PCR result confirmed increased Cyclin D1 and D2 in Hand1-DD hearts (Figure S1A and S1B). Interestingly, genes involved in oxidative phosphorylation and citrate cycle (TCA cycle) were found with reduced expression in Hand1-DD hearts (Table S1). Cyclin D1 (Cond1) and cyclin D2 (Cond2) were also up-regulated in Hand1-DD hearts and genes encoding collagen isoforms were high in both Hand1-DD and –AA hearts consistent with fibrosis revealed by histological study (Table S1 and Figure 1H).

We first detected Twist1 expression in mouse tissues by RT-PCR and the result indicated that Twist1 was ubiquitously expressed with varied amount (Figure 2A). In particular, we found that Twist1 was expressed in heart ventricles (Figure 2A). Using a similar strategy for generation of Hand1 TG mice, we obtained Twist1-WT and -DD transgenic TG mice and found that while WT TG mice had comparable heart to control mice, Twist1-DD TG mice displayed hyper trophy and some of them had atrial septal defect (ASD) and ventricular septal defect (VSD) (Figure 2B–D). Echo analysis indicated impaired heart function in Twist1-DD mice compared to WT mice (Table 2 and Figure 2E and 2F).

**Hand1 and Twist1 could be phosphorylated by Akt in vitro and in vivo**

An in vitro phosphorylation assay using GST-Hand1 fusion protein demonstrated that mouse Hand1 could be phosphorylated by Akt at two residues, T107 and S109 (Figure 3A). Mutation of these two amino acids to alanine (A) in Hand1 abolished phosphorylation by Akt (Figure 3A). The phosphorylation sites were also confirmed by mass spectrometric analysis of GST-Hand1 after Akt kinase assay, which identified phospho-Hand1 peptide (Figure 3B). Western blotting analysis using a phospho-specific Hand1 antibody also showed Hand1 to be phosphorylated at both T107 and S109 (Figure 3C).

The results so far all indicated that Akt phosphorylated Hand1 in vitro. We next studied Hand1 phosphorylation by Akt in cultured mammalian cells by an in vitro biochemical assay. HA-Hand1 expressed in HEK293 cells alone or together with constitutively active Akt was pulled down by immunoprecipitation (IP) (Figure 3D). After SDS-PAGE and Coomassie blue staining, Hand1 bands were excised and analyzed by mass spectrometry (Figure 3D). No phospho-peptides were found in bands of Hand1 without co-transfection of Akt (Bands2–4 in Figure 3D), but phospho-peptides with the sequence profile of RTpESINSAFAELR and RTESpINSFAELR (with phosphorylation on T107 or S109) were identified in bands co-expressed with Akt (Bands 5–
8 in Figure 3D). Furthermore, we examined Hand1 phosphorylation by Akt with phospho-specific antibody. In cells expressing wild-type Hand1 and Hand1-DD (to mimic phosphorylation), a phospho-band could be detected and the signal became stronger in the presence of constitutively active Akt (m/p-Akt) while there was no band with cells expressing Hand1-AA (to abolish phosphorylation) (Figure 3E). In addition, we studied Hand1 phosphorylation by Akt with insulin stimulation. Cells were starved over-night by serum withdrawal, and treated with insulin to activate Akt (Figure 3F). Akt activation brought about Hand1 phosphorylation which was blocked by LY-294002 (LY), an inhibitor of PI3K-Akt signaling (Figure 3F). Similarly, Twist1 could also be phosphorylated by Akt (Figure 3G and Figure S2). Furthermore, we also tested Hand1/Twist1 phosphorylation by Akt in cultured cardiomyocytes and the results were consistent with those performed in HEK293 cells (Figure 3H). Collectively, these results indicate that Hand1 and Twist1 are bona fide Akt substrates.

Akt suppressed Hand1 activation of reporter gene transcription

Previous studies have shown that Hand1 forms heterodimers with class A E-factors such as E12 and E47 to activate or suppress transcription of downstream target genes via binding the “E-box” sequence (CANNTG) or the degenerate “D-box” sequence (CGTCTG) [2,6,7,11]. Hand1 and Hand2 are close isoforms, and their bHLH motives are nearly identical. It has been found that the basic domain of Hand2 (RRR109-111) was crucial for DNA binding and mutation of RRR109-111 to EDE abolished Hand2 DNA binding and activation of reporter luciferase gene transcription [34]. Akt1 phosphorylated Hand1 in the basic-helix motif and might have similar function as Hand2 RRR109-111EDE mutant [34]. Akt1 phosphorylated Hand1 in the basic-helix motif and might have similar function as Hand2 RRR109-111EDE mutant [34].

Next, we studied Hand1/E12 DNA binding ability after phosphorylation by gel shift and ChIP assay. As shown in Figure 5B, Hand1-DD was abolished from DNA binding while Hand1-AA displayed strong DNA binding ability. Furthermore, ChIP assay also demonstrated that Hand1-DD had a much weaker DNA binding ability than Hand1-WT and -AA (Figure 5C). Consistently, Akt reduced Hand1 DNA binding ability (Figure 5C). Similar to reporter gene regulation assay, phosphorylation of Hand1 showed the same effects on DNA binding as Hand2RRR109-111EDE mutant [34].

**Discussion**

Our study has demonstrated that phosphorylation of Twist1 family played a critical role in heart remodeling in mouse models and provided insights into the regulation of Twist1 family in heart remodeling. This study indicated that the Twist1 family was

---

### Table 1. Echocardiography of 8- to 10-week-old Hand1 TG mice.

|                | Con (n = 5) | Hand1WT89low TG (n = 5) | Hand1AA26low TG (n = 5) | Hand1DD2low TG (n = 6) |
|----------------|------------|-------------------------|-------------------------|------------------------|
| F5%            | 33.09 ± 3.80 | 29.07 ± 4.72            | 20.70 ± 4.41*           | 17.40 ± 8.84*          |
| EF%            | 62.67 ± 5.27 | 56.61 ± 7.29            | 41.44 ± 6.89            | 35.89 ± 7.44*          |
| LVID; s (mm)   | 2.27 ± 0.37  | 2.49 ± 0.34             | 2.43 ± 0.29             | 3.06 ± 0.56*           |
| LVPW; d (mm)   | 0.73 ± 0.06  | 0.84 ± 0.21             | 0.68 ± 0.07             | 0.70 ± 0.11            |
| LVPW; s (mm)   | 1.10 ± 0.05  | 1.14 ± 0.17             | 0.81 ± 0.07*            | 0.87 ± 0.19*           |
| LV Vol; d (µl) | 47.19 ± 12.08| 51.35 ± 9.38            | 46.17 ± 11.37           | 79.41 ± 20.11          |
| LV Vol; s (µl) | 18.14 ± 6.63 | 22.75 ± 7.20            | 21.22 ± 6.16            | 56.45 ± 10.34          |

*P<0.05 compared with control.

Abbreviations: EF, ejection fraction; F5, fractional shortening; LVID, left ventricular internal; LVPW, left ventricular posterior wall; LV Vol, left ventricular volume; d, diastolic; s, systolic.

doi:10.1371/journal.pone.00019251.t001
involved not only in embryonic heart development but also in post-natal heart function. Previous studies have revealed an essential role of Twist1 for embryonic development including cardiac neural crest and valve morphogenesis [35,36,37]. Our work suggests that phosphorylation of Twist1 family may also regulate embryonic development. Work performed by Olson’s group supports this hypothesis. They have shown that the basic domain of Hand2 (RRR109-111) is crucial for DNA binding and regulation of target gene expression. Mutation of RRR109-111 to EDE abolished Hand2 DNA binding and activation of luciferase reporter gene transcription [34]. In mice, RRR109-111EDE mutation caused embryonic lethality at around E10.5 and right ventricular hypoplasia [38]. Obviously, mutation of the basic domain disrupts the consensus motif of Hand2 and abolishes phosphorylation. The Twist1 family members of Hand1, Hand2, Twist1 and Twist2 possess a well-conserved basic-helix I motif that contains threonin and serine. Among them, Hand1, Hand2 and Twist1 were previously reported to be phosphorylated by PKA, PKC and Plk4 at the two residues of threonin and serine [9,12,13]. Another study showed that Hand2 could be phosphorylated at the same residues by Akt [39]. Phosphorylation of these Twist1 family members regulates developmental process and cell fate determination such as limb formation and trophoblast differentiation [9,10,12,13]. Studies of mutant mice have shown that Hand1, Hand2 and Twist1 play a critical role in heart development [5,8,14,15]. Hand1 and Hand2 were found involved in the development of cardiomyopathy in rodents and human [16,17]. In the future, generation of inducible/conditional knock-in mutation

Table 2. Echocardiography of 20-day Twist1 TG mice.

|                  | WT (n = 6) | Twist1DD (n = 7) |
|------------------|------------|------------------|
| IVS; d (mm)     | 0.59±0.02  | 0.72±0.03        |
| LVID; d (mm)    | 2.68±0.04  | 2.72±0.07        |
| LVPW; d (mm)    | 0.61±0.01  | 0.71±0.05        |
| IVS; s (mm)     | 0.69±0.03  | 0.72±0.03        |
| LVID; s (mm)    | 1.61±0.03  | 2.24±0.07*       |
| LVPW; s (mm)    | 0.87±0.02  | 0.76±0.05        |
| LV Vol; d (l)   | 26.84±0.91 | 28.57±1.50       |
| LV Vol; s (l)   | 7.49±0.42  | 18.21±1.07**     |
| EF %            | 72.02±1.25 | 38.43±2.11**     |
| FS %            | 39.96±1.04 | 18.20±1.20**     |
| LV Mass (mg)    | 41.31±0.72 | 54.98±3.46       |
| LV Mass Corrected (mg) | 33.05±0.57 | 43.98±2.77       |

*P<0.05 and **P<0.005.

Abbreviations: IVS, interventricular septum; LVID, left ventricular internal; LVPW, left ventricular posterior wall; LV Vol, left ventricular volume; EF, ejection fraction; FS, fractional shortening; d, diastolic; s, systolic.
Figure 3. Hand1 and Twist1 could be phosphorylated by Akt in vitro and in vivo. A. Autoradiography of an in vitro phosphorylation assay showing that Akt phosphorylates Hand1 at both Thr107 (T107) and Ser109 (S109). ΔPH-Akt is an Akt mutant without the PH domain and is constitutively active. T107A and S109A are Thr107 and Ser109 mutations to alanine that block phosphorylation. B. SDS-PAGE gel showing separation of GST-Hand1 and GST-Akt after an in vitro phosphorylation assay. The GST-Hand1 band (framed in red) was excised from SDS-PAGE gel and applied to Mass spectrometric analysis. The result confirmed Hand1 phosphorylation by Akt. C. Western blot using phospho-Hand1-specific antibody to detect Hand1 phosphorylation by Akt. D. GST-Hand1 band (framed in red) was excised from SDS-PAGE gel and applied to Mass spectrometric analysis. The result confirmed Hand1 phosphorylation by Akt. E. No phospho-peptide was detected in bands 2–4 specific antibody. The similar effects were observed in GST-HA-Hand1T107A protein, S109 could be phosphorylated by Akt and detected with the phospho-specific antibody. F. Study of Hand1 phosphorylation in HEK293 cells with insulin to activate Akt. After transfection, cells were starved overnight by withdrawal of serum from medium and insulin was added to the cells for 15 minutes resulting in Akt phosphorylation and activation. Activation of Akt, in turn, phosphorylated Hand1. This is blocked by LY204002 (LY), a PI3K inhibitor. F-Akt represents Akt phosphorylation and activation. G. Study of Twist1 phosphorylation in HEK293 cells as for Hand1. H. Test of Hand1/Twist1 phosphorylation by Akt in mouse cardiomyocytes.

doi:10.1371/journal.pone.0019251.g003

mice will make it possible to explore the role of Twist1 family phosphorylation in post-natal heart function.

In this study, we found that phosphorylation of Hand1 suppressed its transcriptional activity. Previously, Firulli and colleagues performed comprehensive study of Twist1-ΔA and Twist1-DD mutation on transcriptional activity regulation and their results indicated that both reduced gene transcription of luciferase reporters [10]. In human patients with cardiomyopathy as well as rodent models of cardiac hypertrophy, Hand1 gene expression levels were found reduced suggesting a correlation between Hand1 levels and heart remodeling [16,17]. Combined with our transgenic mouse models, these studies suggest that Twist1 and Hand1 may play a growth-inhibitory role in post-natal heart and phosphorylation may release their inhibitory effects leading to hypertrophy. Data obtained from microarray analysis supports this hypothesis because we found increased expression levels of growth-promoting genes including Fgf1r, Fgf12, Igf1, Igf1r, Cyclo D2 in Hand1-DD heart. Interestingly, the genes involved in oxidative phosphorylation and TCA (citrate) cycle were found with reduced levels in Hand1-DD heart suggesting that decreased metabolism may result in heart failure [40].

Previously, it was reported that Akt phosphorylated Hand2 in vitro and phosphorylation negatively regulated Hand2 DNA binding and activation of luciferase reporter gene expression [39]. Our results are consistent with this study. However, how Hand2 phosphorylation functions in heart development and remodeling remains unknown. In the future, it will be necessary to study this Akt-Hand2 relationship in mice because of distinct expression pattern of Hand1 and Hand2 in left and right ventricles [2].

The role of Akt in pathological heart remodeling has been intensively investigated by studying transgenic mice with Akt overexpression in cardiomyocytes [18,20,22,23,24,25,26,27,28,29,41,42,43,44]. These studies have demonstrated that aberrant activation of Akt in cardiomyocytes gave rise to pathological hypertrophy. On the other hand, reduction of Akt activity in cardiomyocytes resulting from deletion of its upstream kinase, PDK1, also caused pathological cardiac remodeling (dilated cardiomyopathy and heart enlargement) [43,46]. Using zMice-Gre, we deleted PDK1 in cardiomyocytes and obtained similar results (data not shown). Gene expression study indicated increased expression levels of Igf1 and its receptor in Hand1-DD heart, which suggested that IGF1-PDK1-Akt-Hand1 positive feedback loop might contribute greatly to the phenotype. This needs to be tested in the future.Taken together, these studies suggest that the Twist1 family might be the key downstream players in heart hypertrophy/dilation induced by abnormal Akt signaling (enhancement or reduction).

Intriguingly, Hand1S109G mutation in the phosphorylation motif has been identified in human VSD heart sample pinpointing the role of phosphorylation regulation of Hand1 in heart development [47]. In the future, it will be worthwhile to search for Hand1 mutations in patients with pathological heart remodeling, such as hypertrophic and dilated cardiomyopathy (HCM and DCM).

In summary, we have identified a novel regulatory mechanism of Twist1 family involved in cardiac remodeling. Our work suggests that modulation of Akt activity (enhancement or reduction) by agonists or inhibitors may have therapeutic application on pathological cardiac remodeling. Meanwhile, this study puts caution on pharmacological development of inhibitors to suppress PI3K-Akt signaling against tumor growth in that reduction of Akt signaling may have severe cardiac toxicity.

Materials and Methods

Chemicals and antibodies

LY-294002 (cat# 440202) was from Calbiochem and insulin from Sigma. The following antibodies were from Cell Signaling Technology (CST): total Akt (9272), pSer473 phospho-Akt antibody (9271), Twist1 (4119) and Tubulin (2148). Pan-actin antibody (MS-1295-P0) and HRP-linked secondary antibodies (Prod #31460 and Prod #31430) were from Thermos Scientific. The HA (FMI 4213) and Myc (9E10) antibodies were from a hybridoma cell culture supernatant maintained in the authors’ laboratory.

Plasmids construction

Mouse Hand1 cDNA was cloned from E14.5 placenta by RT-PCR and the two primer sequences were: forward, BamH I GGA TCC ACC (HA tag) ATG GCT TAC CCA TAC GAT GTT CCA GAT TAC GCT TCC (Hand1-5’); reverse, BamH I GGA TCC (Hand1-3’) TCA CTG GTT TAG CTC CAG CGC. The PCR product is 699 bp encoding a protein of 227 amino acids (including12 amino acids of the HA tag). The PCR product was further cloned into pGEMT-easy to generate pGEMT-easy-HA-mHand1 and verified by sequencing. For mammalian expression vector construction, pGEMT-easy-HA-mHand1 was digested with BamH I and the fragment (699 bp) released was subcloned into pCMV5 at a BamH I site and the fragment (699 bp) released was subcloned into pCMV5 at a BamH I site, resulting in pCMV5-HA-mHand1; the orientation was verified by HindIII digest. To construct the E. coli expression vector pGEX2T-HA-mHand1, the 699-bp fragment above was subcloned into pGEX2T at a BamHI site and the orientation verified by HindIII digestion.

For mammalian expression vector construction, pGEMT-easy-HA-mHand1 was digested with BamH I and the fragment (699 bp) released was subcloned into pCMV5 at a BamH I site, resulting in pCMV5-HA-mHand1; the orientation was verified by HindIII digest. To construct the E. coli expression vector pGEX2T-HA-mHand1, the 699-bp fragment above was subcloned into pGEX2T at a BamHI site and the orientation verified by HindIII digestion.

For mammalian expression vector construction, pGEMT-easy-HA-mHand1 was digested with BamH I and the fragment (699 bp) released was subcloned into pCMV5 at a BamH I site, resulting in pCMV5-HA-mHand1; the orientation was verified by HindIII digest. To construct the E. coli expression vector pGEX2T-HA-mHand1, the 699-bp fragment above was subcloned into pGEX2T at a BamHI site and the orientation verified by HindIII digestion.

For mammalian expression vector construction, pGEMT-easy-HA-mHand1 was digested with BamH I and the fragment (699 bp) released was subcloned into pCMV5 at a BamH I site, resulting in pCMV5-HA-mHand1; the orientation was verified by HindIII digest. To construct the E. coli expression vector pGEX2T-HA-mHand1, the 699-bp fragment above was subcloned into pGEX2T at a BamHI site and the orientation verified by HindIII digestion.
The mHand1T107AS109A and mHand1T107DS109D mutants were obtained with a site-specific mutagenesis kit (Invitrogen) and the sequences of the two pairs of oligos were:

for T107AS109A, 5'-G AAG GAG AGG AGA CGC GCC ATT AAC AGC GCG TTC-3' and 5'-GAA CGC GCT GTT AAT GGC CTC GTC GCG TCT CCT CTC CTT C-3';

for T107DS109D, 5'-G AAG GAG AGG AGA CGC GCC ATT AAC AGC GCG TTC GCC GCC-3' and 5'-GAA CGC GCT GTT AAT GGC CTC GTC GCG TCT CCT CTC CTT C-3'.

Single amino acid mutants (T107A or S109A) were acquired by a similar strategy. Mouse Twist1 was amplified by PCR using pcDNA3-HA-Twist1 (a gift from Dr. Gerard Karsenty at the Baylor Medical College) as template and the two primers are: (forward) BamHI GGA TCC ACC (HA tag) ATG GCT TAC GCC TAC TAC GTT CCA GAT TAC GCT TCG (Twist1-5'); (reverse) EcoRI GAA TTC (Twist1-3') CTA GTG GGA CGC GGA CAT. The amplified fragment was ligated into pCMV5 for mammalian cell transfection (pCMV5-HA-Twist1).

The mTwist1T125AS127A and mTwist1T125DS127D mutants were obtained with a site-specific mutagenesis kit (Invitrogen) and the sequences of the two pairs of oligos were:

for T125AS127A, 5'-CGG GAG CGC CAG CGC GCG CTC CTG AAC GAG GCG TTC GCC GCC-3' and 5'-GGC GGC GAA CGC CTC GTT CAG GTC GCG CTG GCC-3';

for T125DS127D, 5'-CGG GAG CGC CAG CGC GCG CTC CTG AAC GAG GCG TTC GCC GCC-3' and 5'-GGC GGC GAA CGC CTC GTT CAG GTC GCG CTG GCC-3'.

Single amino acid mutants (T107A or S109A) were acquired by a similar strategy. Mouse Twist1 was amplified by PCR using pcDNA3-HA-Twist1 (a gift from Dr. Gerard Karsenty at the Baylor Medical College) as template and the two primers are: (forward) BamHI GGA TCC ACC (HA tag) ATG GCT TAC GCC TAC TAC GTT CCA GAT TAC GCT TCG (Twist1-5'); (reverse) EcoRI GAA TTC (Twist1-3') CTA GTG GGA CGC GGA CAT. The amplified fragment was ligated into pCMV5 for mammalian cell transfection (pCMV5-HA-Twist1). The mTwist1T125AS127A and mTwist1T125DS127D mutants were obtained with a site-specific mutagenesis kit (Invitrogen) and the sequences of the two pairs of oligos were:

for T125AS127A, 5'-CGG GAG CGC CAG CGC GCG CTC CTG AAC GAG GCG TTC GCC GCC-3' and 5'-GGC GGC GAA CGC CTC GTT CAG GTC GCG CTG GCC-3';

for T125DS127D, 5'-CGG GAG CGC CAG CGC GCG CTC CTG AAC GAG GCG TTC GCC GCC-3' and 5'-GGC GGC GAA CGC CTC GTT CAG GTC GCG CTG GCC-3'.
(T127A or S127D) were acquired by a similar strategy. After mutagenesis, the sequences were verified by sequencing. pCI-E12 was obtained from Martin Knoefler (University of Vienna, Austria), the reporter plasmid of Six1-Luciferase from Paul Riley (University College London), and the ANF-luciferase reporter plasmids from Mona Nemer (University of Ottawa, Canada) and Anning Lin (University of Chicago), respectively.

pCMV5-Myc-E12 was generated by PCR using pCI-E12 as a template and the product was cloned into pCMV5 at EcoRI and BamHI sites. The two primer sequence were: forward, EcoRI GAA TTC ACC (Myc tag) ATG GAA CAA AAA CTT ATT TCT GAA GAA GAT CTG (E12-5\'9) GCG CCT GTG GGC ACA GAC; reverse, BamHI GGA TCC (E12-3\'9) TCA CAT GTG CCC GGC GGG.

pCMV5-myc-mTbx5 was cloned by PCR using the plasmid Tbx5-pcDNA3 from Katherine Yutzey (Cincinnati Children's Hospital Medical Center) as template.

GST-HA-mHand1 fusion protein purification and generation of antibodies

GST-HA-mHand1 wild type, T107A, S109A, and T107A/S109A fusion proteins were produced in E. coli with pGEX2T vectors. 0.1 mM IPTG was used to induce fusion protein production, the majority of which was in the form of inclusion bodies. To purify the fusion protein, the cell pellet was lysed by sonication in PBS containing 2 mM EDTA, 10 mM DTT, 0.5 mM PMSF and 1 mM benzamidine, followed by centrifugation. This step was repeated 2–3 times to wash the inclusion body. Purified inclusion bodies were sonicated again in PBS with 10 mM DTT, 0.1% SDS, and 10% glycerol (which helped dissolve the protein). The supernatant was collected and dialyzed overnight in PBS at 4°C. To generate a Hand1 antibody, a peptide with the sequence IPNVPADTKLSKIKTLRLATSYIA was used to immunize two rabbits after conjugation with exogenous protein (Nanjing Chuanbo Biotech. Co., Ltd.). The anti-sera were affinity purified and tested on cell transfections or mouse heart tissues by western blotting. A similar procedure was used for the generation and purification of Hand1T107pS109p phospho-specific antibody using the peptide sequence KERR RThEhNSAfA (Nanjing Chuanbo Biotech. Co., Ltd.).

Cell culture, transfection, treatment and luciferase reporter assay

HEK293 cells were maintained in DMEM plus 10% fetal bovine serum (Gibco and Hyclone) and transfected using either FuGene HD (Roche) or GenEscort (Nanjing Wisegen Biotech. Co., Ltd) and plasmid amounts of 10 mg per 10-cm dish or 2 mg per well in 6-well plates. For treatment, the cells were first serum-starved for 20 h at 1 day after transfection and then treated with insulin (0.1 mM) for 15 min or LY294002 (20 mM) for 2 h prior to insulin treatment. For the luciferase reporter assay, HEK293 cells were plated into 12-well plates and transfected with 100 ng 6×Th1g luc. plasmid or ANF-luc. plasmid, 10 ng pRL-TK-ren., 100 ng pCI-E12, 100 ng pCMV5-Hand1 wild type or mutants and 100 ng pCMV5-m/p-Akt. In other experiments, different amounts of plasmids were used, as indicated. The total amount of DNA in each treatment was normalized with pCMV5 empty plasmid. Each transfection was performed in duplicate. Cells were collected 48 h after transfection for the dual-luciferase assay using the Promega assay system (Glomax). Each assay was repeated at least three times.

Neonatal mouse cardiomyocyte culture and lentivirus infection

Cardiomyocytes were isolated as previously described [48]. Briefly, hearts were dissected from newborn mice and atria were...
removed. Ventricles were excised to pieces (1 x 1 mm) and incubated in collagenase (type 2, Sigma) at 37°C for 10 minutes. Subsequently, supernatants were filtered and cells in supernatants were collected by centrifugation. These cells were cultured in DMEM plus 10% fetal bovine serum (Hyclone). Most of the cells started to beat after 24 hours of culture. For lentiviral construction, a system including lentiviral vector FuGW (ubiquitin promoter), envelope plasmid pMD1.G and packaging plasmid pSPAX2 was used (a gift from Dr. Ying Wan at Department of Laboratory Animal Science, Third Military Medical University, China). Coding sequences of Hand1, Twist1 and Akt1 were obtained from pCMV5-36HA-Hand1, pCMV5-36HA-Twist1 and pCMV5-Flag-Akt1 and ligated into FuGW at the BamH1 and EcoRI sites. Lentivirus was prepared as described in Tronolab (http://tronolab.epfl.ch). Briefly, about 4 x 10^6 293FT cells were plated in a 10 cm cell culture dish. At 80-90% confluency, the cells were co-transfected with 5 μg of envelop plasmid, 15 μg of packaging plasmid and 20 μg of lentiviral vector using calcium phosphate precipitation. After 9 h, the medium was removed and 10 ml of fresh DMEM plus 10% FBS (Hyclone) was added to each dish. 48 h later, supernatant was collected and 1 ml of supernatant was added to the neonatal mouse cardiomyocytes cultured in 6-well plate for cell infection. 24 h later, the medium was removed and 3 ml of fresh DMEM plus 10% FBS (Hyclone) was added to each well. 48 h later about 80% of cells were GFP positive and cells were collected for analysis.

**In vitro and in vivo phosphorylation assay**

Phosphorylation of GST-Hand1 and mutants were carried out at 30°C for 30 minutes in a volume of 50 μl of kinase assay buffer containing GST-Hand1 or mutants, hot-ATP and active Akt. The samples were subjected to SDS-PAGE followed by autoradiography. For mass spectrometric assay, bands (GST-Hand1 or HA-Hand1 from immunoprecipitation) were excised from SDS-PAGE gel for in-gel tryptic digestion and the peptides were separated by capillary liquid chromatography tandem mass spectrometry (LC-MSMS) using a Magic C18 100 μm x 10 cm HPLC column (Swiss BioAnalytics, Switzerland) on a 1100 Nano-HPLC system (Agilent, Palo Alto, CA) connected on line to a 4000 Q Trap (MDS Sciex, Concord, Ontario, Canada) [19]. MASCOT searching SwissProt 57.6 was used to identify the phosphopeptides. Individual spectra were further evaluated manually.

**Western blotting analysis and immunoprecipitation**

Cells and hearts were collected and snap-frozen in liquid nitrogen until use. Cell/tissue lysates were prepared in lysing buffer (20 mM Tris, 150 mM NaCl, 10% glycerol, 20 mM glycerophosphate, 1% NP40, 5 mM EDTA, 1 mM Na3VO4, 0.5 mM PMSF, 1 mM benzamidine, 1 mM DTG, 50 mM NaF, 4 mM leupeptin, at pH 8.0). Samples were resolved by 10% SDS-PAGE and transferred to PVDF membranes (Millipore). Membranes were blocked with 5% non-fat milk in TBST (50 mM Tris, 150 mM NaCl, 0.5 mM Tween-20, pH 7.5) and incubated with primary antibodies overnight at 4°C. Immunoprecipitation was performed using protein A sepharose CL-4B beads (Amersham-Pharmacia).

**Gel shift assay**

Nuclear extracts from HEK293 cells overexpressing Hand1-AA and Hand1-DD were prepared using a nuclear extract kit (Active motif) according to manufacturer's instructions. Oligonucleotides containing a consensus Hand1 binding site (Th1 D-box) that was described previously were synthesized as follows: (Sense) 5'-ATTGGGCGTGTGCATTGCGATTGTCGACATTGCAATTGACATTG-3'; (Antisense) 5'-GATCTGAATGCCAGCCGATGCAATGCGAAGCAGCAGCATTGAATGAGCT-3'. The samples were subjected to SDS-PAGE followed by autoradiography. For mass spectrometric assay, bands (GST-Hand1 or mutants, hot-ATP and active Akt) were excised and separated by capillary liquid chromatography tandem mass spectrometry. Mass spectrometric data were searched in the SWISS-PROT database using the software SEQUEST [19].

**ChIP assay**

Cell lysates and nuclear extracts were prepared from HEK293 cells over expressing HA-Hand1-WT, HA-Hand1-AA, HA-Hand1-DD and HA-m-p/AKT plus HA-Hand1-WT, respectively. The 6×Xing1 DNA fragment containing six successive Hand1 D-box (CGTCTG) sequences was prepared by kpnI and SmaI digestion from 6× Xing1 luc vector. The nuclear extracts and 6×Xing1 DNA fragment were incubated in 5× binding buffer (20% glycerol, 5 mM MgCl2, 2.5 mM EDTA, 2.5 mM DTT, 250 mM NaCl, 50 mM Tris-HCl (pH 7.5), 0.25 mg/ml poly(dI-dC)poly(dI-dC)) for 30 minutes at room temperature. Immunoprecipitation was performed using HA antibody (1:100) according to the manufacturer's instructions of Upstate ChIP assay kit. DNA was recovered by phenol/chloroform extraction and ethanol precipitation. The following PCR primers against 6× Xing1 fragment were used as follows: 5'-CATTTGGCGTCTGGCAATTGATG-3' and 5'-AGCTCAATGACGCAATTG-3'.

**Mice**

Mice were housed in accordance with the regulations on mouse welfare and ethics of Nanjing University in groups with 12-h dark-light cycles and free access to food and water. The experimental animal facility has been accredited by AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care International) and the IACUC (Institutional Animal Care and Use Committee) of Model Animal Research Center of Nanjing University approved all animal protocols used in this study. Hand1 and Twist1 transgenic mice were generated through pro-nuclear injection of plasmid DNA. HA-Hand1, HA-Twist1 wild-type and mutants were ligated into alpha-MyHC clone 26 (a gift from Dr. Jeffrey Robbins at the Cincinnati Children’s Hospital Medical Center) at SalI site and the plasmids were linearized with Afil [50]. Founders were genotyped by PCR and expression levels were examined with western blot analysis. Progenies of founders were backcrossed to C57/B6 genetic background. Primers for genotyping of Hand1 TG mice are: forward 5'-GCTGCCATTGCGGATGGCACA-3' and reverse 5'-AGCTCAATGACGCAATTG-3'. The size of PCR product is 450 bp. Primers for genotyping of Twist1 TG mice are: forward 5'-GGGGTTGGATTGCGTCTAAGCGTGATGCACGCAATTG-3' and reverse 5'-GGGTTGGATTGCGTCTAAGCGTGATGCACGCAATTG-3'.

**Echocardiography (Echo)**

Echo was performed with Vevo 660 UBM (VisualSonics, Toronto, ON, Canada) that possesses a single-element mechanical transducer with a center frequency of 30 MHz and a frame rate of 30 Hz. The spatial resolution of B-mode imaging was ~115 μm (lateral) by ~53 μm (axial). Mice were anesthetized with Avertin that was prepared as a 1.2% solution and with Avertin that was prepared as a 1.2% solution and maintained between 36 and 38°C. Echocardiography involved monitoring of heart rate and left ventricular systolic function (LVSF) in groups with 12-h dark-light cycles and free access to food and water. The experimental animal facility has been accredited by AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care International) and the IACUC (Institutional Animal Care and Use Committee) of Model Animal Research Center of Nanjing University.
Histology and immunohistochemical staining

The hematoxylin–eosin (HE) and immunohistochemical (IHC) protocols were as described previously [51,52]. Briefly, hearts were washed with cold PBS and fixed in formalin overnight at 4 °C. The samples were processed successively by (a) a 30-min wash in PBS at 4 °C, (b) a 1-h incubation in 70%, 80%, 95%, and 3×1 h incubation in 100% ethanol at room temperature (RT), (c) 3× 20 min incubation in xylene at RT, (d) a 1-h incubation in paraffin/xylene (1:1) at 65 °C, (e) 3×1 h incubation in fresh paraffin at 65 °C. The processed samples were then embedded in paraffin and sectioned (7 μm thick) and the sections HE stained following the standard protocol. For IHC, frozen-sections were incubated at 4 °C overnight with antibodies for HA and To-Pro 3 iodine (642/661, Molecular Probes). Images were processed with an Olympus confocal microscope system.

Microarray analysis

Three hearts were dissected from each group of control, Hand1-WT, -DD and -AA mice. Total RNA was isolated from each three hearts and was pooled together. In total, four RNA samples were applied for microarray analysis (Allymetrix Mouse 430 2.0 Array, Shanghai Biochip Co. Ltd.). The data was analyzed by use of Molecular Annotation System (Beijing CapitalBio Corporation).

Masson's trichrome staining

Myocardial fibrosis in myocardial infarct mice were detected by masson's trichrome staining. Hearts were cross-sectioned in 6 μm thick and then stained according to the protocol (http://www. ihcworld.com/_protocols/special_stains/masson_trichrome.htm).

Statistics

Data were presented as mean±SD values. For comparisons between two groups, statistical significance was determined using the unpaired two-tailed t-test. A value of P<0.05(*) was considered statistically significant and P<0.01(**) statistically very significant.

Supporting Information

Figure S1 A. Analysis of gene expression in Hand1 TG hearts by RT-PCR. Three individual hearts for each group were analyzed. * indicates up-regulation in –AA and –DD hearts compared to control and –WT. B. Quantitation of A. *, represents P<0.05. C. RT-PCR analysis of total Hand1 expression in multiple tissues of TG mice.

Figure S2 Study of Twist1 phosphorylation by Akt in U2OS cells.

Table S1 Microarray analysis of Hand1 TG hearts (DOC)

Acknowledgments

We thank Dr. Paul Riley (University College London) for the 6×Thioguanine-luciferase reporter plasmid, Dr. Martin Knoedler (University of Vienna) for the pCI-E12 plasmid, Dr. Mona Nemer (University of Ottawa) and Dr. Anning Liu (University of Chicago) for the ANF-luciferase reporter plasmids, and Dr. Jeffrey Robbins and Katherine Yutzey (Cincinnati Children’s Hospital Medical Center) for the plasmids of z-MyHC clone 26 and Tbx5-pcDNA3, and Dr. Gerard Karsenty at the Baylor Medical College for pcDNA3-Twist1 plasmid. We are also indebted to Jing Zhang, Pengyu Gu, Juan Xu and Honglan Xue (Moue Facility of Model Animal Research Center, Nanjing University) for pronuclear injection and maintenance of the transgenic mice.

Author Contributions

Conceived and designed the experiments: ZY SL JN QL BAH. Performed the experiments: ZY SLJN QL QF DH. Analyzed the data: ZY SLJN QF QL DH BAH. Contributed reagents/materials/analysis tools: ZC QX CS. Performed the experiments: ZY SL JN QL QF DH. Contributed reagents/materials/analysis tools: ZC QX CS. Analyzed the data: ZY SL JN QF.

References

1. Barnes R, Firulli A (2009) A twist of insight—the role of Twist-family bHLH factors in development. The International journal of developmental biology 53: 909.
2. Firulli A (2003) A HANDful of questions: the molecular biology of the heart and neural crest derivatives (HAND)-subclass of basic helix-loop-helix transcription factors. Gene 312: 27–40.
3. Massari M, Murre C (2000) Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms. Molecular and Cellular Biology 20: 429.
4. Simonato E, Ledent V, Richards G, Thomas-Chollier M, Kerner P, et al. (2007) Origin and diversification of the basic helix-loop-helix gene family in metazoans: insights from comparative genomics. BMC evolutionary biology 7: 33.
5. Firulli A, McFadden D, Lin Q, Srivastava D, Olson E (1998) Heart and extra-embryonic mesodermal defects in mouse embryos lacking the bHLH transcription factor Hand1. Nature Genetics 18: 266–270.
6. Hill A, Riley P (2004) Differential Regulation of Hand1 Homodimer and Hand1-E12 Heterodimer Activity by the Cofactor FHL2. Molecular and Cellular Cardiology 33: 1607–1614.
7. Hollemberg S, Sternbauer R, Cheng P, Weinraub H (1995) Identification of a new family of tissue-specific basic helix-loop-helix proteins with a two-hybrid system. Molecular and Cellular Biology 15: 3813–3822.
8. Riley P, Anson-Cartwright L, Cross J (1998) The Hand1 bHLH transcription factor is essential for placentaion and cardiac morphogenesis. Nature Genetics 18: 271–275.
9. Firulli B, Krawchuk D, Centonze V, Yarovsky N, Vinchup D, et al. (2005) Altered Twist 1 and Hand 2 dimerization is associated with sac6ht-chozten syndrome and limb abnormalities. Nature Genetics 37: 383–388.
10. Firulli B, Redick B, Conway S, Firulli A (2007) Mutations within helix I of Twist1 result in distinct limb defects and variation of DNA binding affinities. Journal of Biological Chemistry 282: 27336.
11. Kimerber S, Husseim P (2002) Human Hand1 basic helix-loop-helix (bHLH) protein: extra-embryonic expression pattern, interaction partners and identification of its transcriptional repressor domains. Biochemical Journal 361: 641–651.
12. Firulli B, Howard M, McDaid J, McBreavey L, Dionne K, et al. (2003) PRA, PKC, and the Protein Phosphatase 2A Influence HAND Factor Function A Mechanism for Tissue-Specific Transcriptional Regulation. Molecular Cell 12: 1225–1237.
13. Martinod D, Riebro C, Smart N, Franco-Viseras M, Rosario C, et al. (2007) Nuclear release of Hand1 acts as a molecular switch to determine cell fate. Nature Cell Biology 9: 1111–1114.
14. McFadden D, Barbosa A, Richardson J, Schneider M, Srivastava D, et al. (2005) The Hand1 and Hand2 transcription factors regulate expansion of the embryonic cardiac ventricles in a gene dosage-dependent manner. Development 132: 189–201.
15. Srivastava D, Thomas T, Liu Q, Kirby M, Brown D, et al. (1997) Regulation of cardiac mesodermal and neural crest development by the bHLH transcription factor, dHAND. Nature genetics 16: 154–160.
16. Natarajan A, Yamagushi H, Ahmad F, Li D, Roberts R, et al. (2001) Human eHAND, but not dHAND, is Down-regulated in Cardiomyopathies. Journal of Molecular and Cellular Cardiology 33: 1607–1614.
17. Thantaliyath B, Livi C, Steinheimer M, Toney C, Firulli A (2002) HAND1 and HAND2 are expressed in the adult-rodent heart and are modulated during cardiac hypertrophy. Biochemical and Biophysical Research Communications 297: 870–875.
18. Heineke J, Molkenstijn J (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. Nature Review Molecular Cell Biology 7: 589–600.
19. Hunter J, Chen K (1999) Signaling Pathways for Cardiac Hypertrophy and Failure. New England Journal of Medicine 341: 1276–1283.
20. O’Neill B, Abel E (2000) Akt1 in the cardiovascular system: friend or foe? Journal of Clinical Investigation 115: 2059–2064.
21. Olson E, Schneider M (2003) Sizing up the heart: development redux in disease. Genes & Development 17: 1937–1936.
22. Shigemura I, Walsh K (2002) Role of Akt signaling in vascular homeostasis and angiogenesis. Circulation Research 90: 1243–1250.
23. Walsh K (2006) Akt Signaling and Growth of the Heart. Circulation 113: 2032–2034.
24. Consonni G, Drusco A, Stassi G, Bellacosa A, Roncagati R, et al. (2002) Akt
induces enhanced myocardial contractility and cell size in vivo in transgenic
mice. Proceedings of the National Academy of Sciences 99: 12333–12338.
25. Cook S, Matsui T, Li L, Rosenzweig A (2002) Transcriptional Effects of Chronic
Akt Activation in the Heart. Journal of Biological Chemistry 277: 22520–22533.
26. Kovacic S, Solty C, Barr A, Shojaee I, Walsh K, et al. (2003) Akt Activity
Negatively Regulates Phosphorylation of AMP-activated Protein Kinase in the
Heart. Journal of Biological Chemistry 278: 39422–39427.
27. Shi T, McMullen J, Kang P, Douglas P, Obata T, et al. (2002) Akt/Protein
Kinase B Promotes Organ Growth in Transgenic Mice. Molecular and Cellular
Biology 22: 2799–2809.
28. Shojaee I, Sato K, Izumiya Y, Schick E, Ito M, et al. (2003) Misexpression of
dHAND in the heart results in progression from adaptive to maladaptive
hypertrophy. Journal of Molecular and Cellular Cardiology 38: 373–385.
29. Woodgett J (2005) Recent advances in the protein kinase B signaling pathway.
Current opinion in cell biology 17: 150–157.
30. Breckenridge R, Zuberi Z, Gomes J, Orford R, Dupays L, et al. (2009)
Overexpression of the transcription factor Hand1 causes predisposition to
arrhythmia in mice. Journal of Molecular and Cellular Cardiology 47: 133–141.
31. Muslin A, DeBosch B (2006) Role of Akt in cardiac growth and metabolism.
Novartis Foundation symposium 274: 119–126.
32. Obenauer J, Cantley L, Yaffe M (2003) Scansite 2.0: Proteome-wide prediction
of cell signaling interactions using short sequence motifs. Nucleic acids research
31: 3635.
33. McDadden DG, McAnally J, Richardson JA, Charite J, Olson EN (2002)
Misexpression of dHAND induces ectopic digits in the developing limb bud in
the absence of direct DNA binding. Development 129: 3077–3088.
34. Chen Z, Behringer R (1995) twist is required in head mesenchyme for cranial
neural tube morphogenesis. Genes & Development 9: 686.
35. Shkolnyk E, Yutzy K, Brazil D, Yang Z, Hemmings B, et al. (2003) Akt1-dependent phosphorylation negatively regulates the transcriptional activity of
dHAND by inhibiting the DNA binding activity. European Journal of
Biochemistry 271: 3330–3339.
36. Jia H, Kelly D (2005) Mitochondrial energy metabolism in heart failure: a
question of balance. Journal of Clinical Investigation 115: 547–555.
37. Cangi D, Yang M, Hemmings B (2004) Advances in protein kinase B signalling:
AKTion on multiple fronts. Trends in Biochemical Sciences 29: 233–242.
38. DeBosch B, Treskov I, Lups T, Weinheimer C, Kovacs A, et al. (2006) Akt1 is
required for physiological cardiac growth. Circulation 113: 2097–2104.
39. Dummler B, Hemmings B (2007) Physiological roles of PKB/Akt isoforms in
development and disease. Biochemical Society Transactions 35: 231–235.
40. Yang Z, Tschopp O, Baudry A, Dummier B, Hyns D, et al. (2004) Physiological
functions of protein kinase B/Akt. Biochemical Society Transactions 32:
350–354.
41. Focuses W, Contact N (2003) Deficiency of PDK1 in cardiac muscle results in
hypertrophy and increased sensitivity to hypoxia. The EMBO Journal 22:
4666–4676.
42. Ito K, Akazawa H, Tamaoka M, Oogawa W, et al. (2009) PDK1 coordinates
survival pathways and β-adrenergic response in the heart. Proceedings of the National Academy of Sciences 106: 8689–8694.
43. Reamon-Buettner S, Cirilli R, Traverso I, Kuhls B, Inga A, et al. (2009) A
functional genetic study identifies HAND1 mutations in septation defects of the
human heart. Molecular Genetics 18: 3567–3578.
44. Borger D, Essig D (1998) Induction of HSP 32 gene in hypoxic cardiomyocytes
functions of protein kinase B/Akt. Biochemical Society Transactions 32:
350–354.
45. Traverso I, Kuhls B, Inga A, et al. (2009) A functional genetic study identifies HAND1 mutations in septation defects of the
human heart. Molecular Genetics 18: 3567–3578.
46. Feng J, Tamaskovic R, Yang M, Brazil D, Meola A, et al. (2004) Stabilization of
Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-
dependent phosphorylation. Journal of Biological Chemistry 279: 35510.
47. Subramaniam A, Jones W, Gulick J, Wang J, Neumann J, et al. (1991) Tissue-
specific regulation of the alpha-musin heavy chain gene promoter in transgenic
mice. Journal of Biological Chemistry 266: 24613.
48. Yang Z, Tschopp O, Hemmings-Miesczak M, Feng J, Brodbeck D, et al. (2003)
Protein Kinase B/Akt1 Regulates Placental Development and Fetal Growth.
Journal of Biological Chemistry 278: 82124–82131.
49. Yang Z, Tschopp O, N D-P, Bruder E, Baudry A, et al. (2005) Dosage-
Dependent Effects of Akt1/Protein Kinase B (PKB) and Akt3/PKB on
Thymus, Skin, and Cardiovascular and Nervous System Development in Mice.
Molecular and Cellular Biology 25: 10407–10418.